Literature DB >> 19939634

Medical application of herpes simplex virus.

Daisuke Watanabe1.   

Abstract

Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) are important human pathogens that cause a variety of diseases from mild skin diseases such as herpes labialis and herpes genitalis to life-threatening diseases such as herpes encephalitis and neonatal herpes. A number of studies have elucidated the roles of this virus in viral replication and pathogenicity, the regulation of gene expression, interaction with the host cell and immune evasion from the host system. This research has allowed the development of potential therapeutic agents and vectors for human diseases. This review focuses on the basic functions and roles of HSV gene products and reviews the current knowledge of medical applications of genetically engineered HSV mutants using different strategies. These major HSV-derived vectors include: (i) amplicons for gene delivery vectors; (ii) replication-defective HSV recombinants for vaccine vectors; (iii) replication-attenuated HSV recombinants for oncolytic virotherapy. Copyright 2009 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19939634     DOI: 10.1016/j.jdermsci.2009.10.014

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  6 in total

Review 1.  Herpesviral vectors and their application in oncolytic therapy, vaccination, and gene transfer.

Authors:  Susanne M Bailer; Christina Funk; André Riedl; Zsolt Ruzsics
Journal:  Virus Genes       Date:  2017-06-20       Impact factor: 2.332

2.  The efficacy of combination therapy with oncolytic herpes simplex virus HF10 and dacarbazine in a mouse melanoma model.

Authors:  Rui Tanaka; Fumi Goshima; Shinichi Esaki; Yoshitaka Sato; Takayuki Murata; Yukihiro Nishiyama; Daisuke Watanabe; Hiroshi Kimura
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

3.  Interleukin-21 receptor signalling is important for innate immune protection against HSV-2 infections.

Authors:  Sine K Kratholm; Marie B Iversen; Line Reinert; Simon K Jensen; Marianne Hokland; Thomas Andersen; Andrew Rankin; Deborah Young; Sebastian Frische; Søren R Paludan; Christian K Holm
Journal:  PLoS One       Date:  2013-12-16       Impact factor: 3.240

Review 4.  Presage of oncolytic virotherapy for oral cancer with herpes simplex virus.

Authors:  Yoshiaki Yura
Journal:  Jpn Dent Sci Rev       Date:  2016-11-05

5.  Oncolytic activity of HF10 in head and neck squamous cell carcinomas.

Authors:  Shinichi Esaki; Fumi Goshima; Haruka Ozaki; Gaku Takano; Yoshimi Hatano; Daisuke Kawakita; Kei Ijichi; Takahiro Watanabe; Yoshitaka Sato; Takayuki Murata; Hiromitsu Iwata; Yuta Shibamoto; Shingo Murakami; Yukihiro Nishiyama; Hiroshi Kimura
Journal:  Cancer Gene Ther       Date:  2019-09-03       Impact factor: 5.987

6.  Genome-wide prediction of vaccine targets for human herpes simplex viruses using Vaxign reverse vaccinology.

Authors:  Zuoshuang Xiang; Yongqun He
Journal:  BMC Bioinformatics       Date:  2013-03-08       Impact factor: 3.169

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.